Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Cogent Biosciences Inc shares valued at $332,412 were purchased by Pinnow Cole on Jan 14 ’25. At $7.60 per share, Pinnow Cole acquired 43,750 shares. The insider’s holdings grew to 45,848 shares worth approximately $0.33 million following the completion of this transaction.
As published in their initiating research note from Scotiabank on March 07, 2025, Cogent Biosciences Inc [COGT] has been a Sector outperform and the price target has been revised to $17. Analysts at Needham downgraded the stock from ‘”a Buy”‘ to ‘”a Hold”‘ outlook in a report released in mid December. As of February 26, 2024, Robert W. Baird has decreased its “an Outperform” rating to a “Neutral” for COGT. Earlier on February 08, 2024, Citigroup initiated its rating. Their recommendation was “a Buy” for COGT stock.
Analyzing COGT Stock Performance
On last trading session,, Cogent Biosciences Inc [NASDAQ: COGT] plunged -4.99% to $7.24. During the last five days, there has been a drop of approximately -0.28%. Over the course of the year, Cogent Biosciences Inc shares have dropped approximately -7.18%. Shares of the company reached a 52-week high of $10.15 on 01/30/25 and a 52-week low of $3.72 on 04/09/25.
Support And Resistance Levels for Cogent Biosciences Inc (COGT)
According to the 24-hour chart, there is a support level at 7.07, which, if violated, would cause prices to drop to 6.90. In the upper region, resistance lies at 7.56. The next price resistance is at 7.89. RSI (Relative Strength Index) is 65.60 on the 14-day chart, showing neutral technical sentiment.
Which companies own the most shares of Cogent Biosciences Inc (COGT)?
In terms of Cogent Biosciences Inc share price expectations, FactSet research, analysts set an average price target of 14 in the next 12 months, up nearly 83.73% from the previous closing price of $7.62. Analysts anticipate Cogent Biosciences Inc stock to reach 14 by 2025, with the lowest price target being 14. In spite of this, 4 analysts ranked Cogent Biosciences Inc stock as Buy at the end of 2025. On December 11, 2023, Wedbush assigned a price target of “a Neutral” to the stock and downgraded coverage with a $5.
